脂肪酸合酶酶水平较高预示上皮性卵巢癌肿瘤细胞减灭术完成率较低。

Higher Level of Fatty Acid Synthase Enzyme Predicts Lower Rate of Completing Debulking Surgery in Epithelial Ovarian Cancer.

机构信息

Department of Obstetrics and Gynecology, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia.

Department of Radiology, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia.

出版信息

Asian Pac J Cancer Prev. 2020 Oct 1;21(10):2859-2863. doi: 10.31557/APJCP.2020.21.10.2859.

DOI:10.31557/APJCP.2020.21.10.2859

PMID:33112541

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7798157/

Abstract

BACKGROUND

The most dominant histopathologic type of ovarian cancer is epithelial ovarian cancer (EOC). Primary debulking surgery determines the treatment success and prognosis of advanced stage EOC. To maintain survival and progression, cancer cells need fatty acid synthase enzyme (FASN). The aim of this study was to evaluate preoperative serum FASN and CA 125 as predictors of primary debulking surgery results in patients with EOC.

METHODS

An observational cross-sectional study was performed on consecutive patients who underwent debulking surgery for suspected ovarian cancer at Dr. Hasan Sadikin Hospital Bandung from 2017 to 2019. Before debulking surgery, blood samples were examined for the serum levels of FASN and CA 125 using ELISA.

RESULTS

There were 53 patients enrolled in this study. Compared with the optimal debulking surgery group, the significant suboptimal debulking surgery group had significantly lower mean serum levels of FASN (0.46 ± 0.144 vs. 0.36 ± 0.128, p = 0.012) and CA 125 (964.22 ± 1722.5 vs. 264.98 ± 251.8, p = 0.002). The cutoff value was highest for the combination of FASN and CA 125 [410.06, area under the curve (AUC) = 77.5% (95% CI 65.5% to 81.9%, p = 0.001)] than for FASN alone [0.375, AUC = 71.3% (95% CI 56.8% to 85.8%, p = 0.009)] and CA 125 alone [222.5, AUC = 75.3% (95% CI 62.5% to 88.1%, p =0.002)].

CONCLUSION

The serum levelof FASN was correlated with suboptimal debulking surgery.

摘要

背景

卵巢癌最主要的组织病理学类型是上皮性卵巢癌（EOC）。初次肿瘤细胞减灭术决定了晚期 EOC 的治疗效果和预后。为了维持生存和进展，癌细胞需要脂肪酸合酶（FASN）。本研究旨在评估术前血清 FASN 和 CA 125 作为预测上皮性卵巢癌患者初次肿瘤细胞减灭术结果的指标。

方法

这是一项在 2017 年至 2019 年期间在万隆哈桑萨迪金医院接受减瘤手术的疑似卵巢癌患者中进行的观察性横断面研究。在减瘤手术前，通过 ELISA 检测血清中 FASN 和 CA 125 的水平。

结果

本研究共纳入 53 例患者。与最佳肿瘤细胞减灭术组相比，明显的次优肿瘤细胞减灭术组的血清 FASN 水平显著降低（0.46 ± 0.144 与 0.36 ± 0.128，p = 0.012）和 CA 125 水平显著降低（964.22 ± 1722.5 与 264.98 ± 251.8，p = 0.002）。FASN 和 CA 125 联合检测的截断值最高[410.06，曲线下面积（AUC）= 77.5%（95%CI 65.5%至 81.9%，p = 0.001）]，高于 FASN 单独检测[0.375，AUC = 71.3%（95%CI 56.8%至 85.8%，p = 0.009）]和 CA 125 单独检测[222.5，AUC = 75.3%（95%CI 62.5%至 88.1%，p = 0.002）]。